FBRX — Forte Biosciences Balance Sheet
0.000.00%
- $150.19m
- $44.04m
- 33
- 31
- 92
- 51
Annual balance sheet for Forte Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 58.8 | 42 | 41.1 | 37.1 | 58.4 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 59.9 | 42.5 | 41.5 | 38.3 | 61.3 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.097 | 0 | — | 0.109 | 0.077 |
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 61.2 | 43.3 | 42 | 39 | 61.6 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 2.26 | 1.76 | 3.18 | 3.67 | 9.08 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 2.26 | 1.76 | 3.18 | 3.67 | 9.08 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 59 | 41.5 | 38.8 | 35.3 | 52.5 |
| Total Liabilities & Shareholders' Equity | 61.2 | 43.3 | 42 | 39 | 61.6 |
| Total Common Shares Outstanding |